HomeCompareIPSAX vs MRK

IPSAX vs MRK: Dividend Comparison 2026

IPSAX yields 16.10% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $395.00 in total portfolio value· pulled ahead in Year 10
10 years
IPSAX
IPSAX
● Live price
16.10%
Share price
$9.28
Annual div
$1.49
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.3K
Annual income
$4,336.64
Full IPSAX calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — IPSAX vs MRK

📍 MRK pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSAXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSAX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSAX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSAX
Annual income on $10K today (after 15% tax)
$1,368.61/yr
After 10yr DRIP, annual income (after tax)
$3,686.14/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $4,910.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSAX + MRK for your $10,000?

IPSAX: 50%MRK: 50%
100% MRK50/50100% IPSAX
Portfolio after 10yr
$57.5K
Annual income
$7,225.21/yr
Blended yield
12.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IPSAX
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSAX buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSAXMRK
Forward yield16.10%2.81%
Annual dividend / share$1.49$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$57.3K$57.7K
Annual income after 10y$4,336.64$10,113.78
Total dividends collected$28.9K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IPSAX vs MRK ($10,000, DRIP)

YearIPSAX PortfolioIPSAX Income/yrMRK PortfolioMRK Income/yrGap
1$12,310$1,610.13$11,213$373.04+$1.1KIPSAX
2$15,024$1,852.42$12,667$512.06+$2.4KIPSAX
3$18,189$2,112.94$14,439$708.14+$3.8KIPSAX
4$21,853$2,390.65$16,640$988.16+$5.2KIPSAX
5$26,067$2,684.31$19,432$1,394.07+$6.6KIPSAX
6$30,884$2,992.46$23,057$1,992.90+$7.8KIPSAX
7$36,359$3,313.52$27,889$2,894.79+$8.5KIPSAX
8$42,550$3,645.77$34,518$4,286.29+$8.0KIPSAX
9$49,516$3,987.42$43,912$6,494.35+$5.6KIPSAX
10← crossover$57,319$4,336.64$57,714$10,113.78$395.00MRK

IPSAX vs MRK: Complete Analysis 2026

IPSAXStock

The fund's primary strategy consists of selling and purchasing put and call options on equity indexes and exchange traded funds. The sale of put options generates income for the fund, but exposes it to the risk of declines in the value of the underlying assets. The risk in purchasing options is limited to the premium paid by the fund for the options. The sale of call options generates income for the fund, but may limit the fund's participation in equity market gains. The fund's investment adviser seeks to reduce the overall volatility of returns by managing a portfolio of options. It is non-diversified.

Full IPSAX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this IPSAX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSAX vs SCHDIPSAX vs JEPIIPSAX vs OIPSAX vs KOIPSAX vs MAINIPSAX vs JNJIPSAX vs ABBVIPSAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.